Technological advances in diagnostic imaging and emphasis on early diagnosis for prevention of diseases are other drivers of the market. The expansion of the healthcare sector and availability of these tests at reputed hospitals and clinics can lend credibility to the trend. Rising number of clinical trials conducted to test the success of drugs for inhibiting the progress of DKD can provide new growth avenues. Angiotensin converting enzyme inhibitors (ACEi) have been known to have moderate success in clinical trials with placebo treatment in reducing the risk of death in patients with diabetes.